The Clinical Challenge of Early Risk Stratification

Relapsing multiple sclerosis (RMS) presents pronounced clinical heterogeneity, making long-term prognosis difficult to anticipate during initial diagnostic evaluation. Clinicians frequently encounter diagnostic uncertainty when forecasting which patients will rapidly develop permanent neurological deficits. Consequently, identifying reliable biomarkers of early disability accumulation at disease onset remains a vital clinical objective. Historically, therapy followed an escalation strategy, starting with modest drugs and advancing only after breakthrough relapses occurred. However, irreversible central nervous system injury often develops quietly during early disease stages. Modern disease-modifying therapies (DMTs) can substantially alter long-term trajectories when initiated early in the disease course. Nevertheless, high-efficacy therapies carry specific safety risks and monitoring requirements, necessitating objective risk stratification tools. Clinicians must balance therapeutic potency against potential adverse events without relying on speculation. By establishing robust prognostic models, neurology teams can tailor interventions to individual patient risk profiles immediately. Integrating routine clinical markers, neuroimaging metrics, and laboratory findings provides a structured roadmap for long-term management. Therefore, evaluating multidimensional diagnostic baselines empowers clinicians to optimize treatment selection and protect functional independence.

Key Prognostic Biomarkers in Newly Diagnosed RMS

Recent research highlights the prognostic value of combining baseline parameters to predict long-term clinical trajectories. In a comprehensive prospective cohort study, investigators examined 417 newly diagnosed RMS patients across a five-year follow-up period. The research team systematically evaluated baseline demographic profiles, neurological assessments, magnetic resonance imaging (MRI) scans, and cerebrospinal fluid (CSF) parameters. Specifically, researchers documented brain and spinal cord lesion counts, initial symptom presentation, and Expanded Disability Status Scale (EDSS) scores during diagnosis. The primary clinical outcome was confirmed disability accumulation (CDA), defined as a sustained EDSS increase lasting at least six months. Over five years, 113 out of 417 participants (27.1%) developed confirmed disability worsening. Researchers performed all-subsets multivariable logistic regression to uncover independent predictors of disease worsening. In addition, the investigators constructed receiver operating characteristic (ROC) curves to assess model discrimination and determine precise individual risk estimates. This rigorous methodology enabled the team to integrate routine clinical and imaging parameters into a unified prognostic instrument for clinical practice.

Deciphering Predictors of Early Disability Accumulation

Multivariable regression analysis identified four independent determinants of early disability accumulation in newly diagnosed patients. First, the presence of intrathecal immunoglobulin G (IgG) synthesis served as a prominent immunologic predictor of progressive disability. Second, a higher baseline burden of spinal cord lesions significantly elevated the risk of physical decline. Third, older age at symptom onset independently correlated with accelerated functional impairment. Finally, a polysymptomatic manifestation at onset contributed substantial risk compared to monosymptomatic presentation. Together, these four variables formed a predictive model achieving an area under the curve (AUC) of 0.75 (95% CI 0.70 to 0.80). Furthermore, the model demonstrated remarkable risk stratification when applying optimal prognostic thresholds. Patients who exceeded baseline thresholds for the top three predictors experienced a 61.8% rate of confirmed disability accumulation within five years. Conversely, individuals who scored below all three thresholds exhibited a disability rate of only 4.5%. Thus, combining these routine diagnostic variables cleanly separates high-risk patients from those with indolent disease trajectories.

Progression Independent of Relapse Activity and Spinal Involvement

Beyond overall disability accumulation, the study evaluated progression independent of relapse activity (PIRA) alongside relapse-associated worsening. Clinicians recognize PIRA as a primary driver of insidious neurological decline, even during periods of complete relapse remission. Notably, the only baseline variable that successfully differentiated PIRA from relapse-associated worsening was the initial number of spinal cord lesions (AUC = 0.64, 95% CI 0.54 to 0.74). The spinal cord contains concentrated motor and sensory pathways within a narrow anatomical space. Consequently, inflammatory lesions in cervical and thoracic segments cause structural vulnerability and accelerate irreversible axonal loss. While brain lesion load reflects total inflammatory activity, spinal cord lesions directly compromise critical motor tracts responsible for ambulation. These findings demonstrate why baseline spinal cord MRI should remain an essential diagnostic standard for all suspected demyelinating cases. By systematically quantifying spinal cord lesions, clinicians gain valuable insights into silent progression and can optimize longitudinal monitoring strategies accordingly.

Translating Multimodal Risk Scores into Clinical Practice

Stratifying disease trajectory at diagnosis offers meaningful clinical advantages for everyday patient care. When newly diagnosed patients present with high-risk features, such as multiple spinal lesions and intrathecal IgG synthesis, clinicians can justify early high-efficacy DMTs. Early treatment with anti-CD20 monoclonal antibodies or high-efficacy oral agents can prevent irreversible functional decline. Conversely, patients presenting with favorable baseline profiles, characterized by younger age, monosymptomatic onset, normal CSF, and no spinal lesions, may achieve stable control on platform therapies. Nonetheless, physicians must maintain regular clinical and MRI surveillance regardless of initial baseline score. Incorporating routine CSF examination for quantitative IgG synthesis alongside comprehensive spinal neuroimaging provides objective risk assessment. Moreover, clinicians should share these individualized risk estimates transparently during shared decision-making discussions. When patients understand their personal risk profile, they demonstrate greater treatment adherence and compliance with monitoring. Ultimately, objective prognostic scores eliminate clinical delays and ensure timely therapeutic optimization before permanent neurological damage occurs.

Implications for Neurological Practice and Future Directions

Modern neurology continues to transition toward personalized precision medicine paradigms for demyelinating conditions. The findings from this cohort show that routine baseline workups contain powerful prognostic data that clinicians frequently underutilize. Baseline evaluations should consistently include dedicated spinal cord MRI along with standard brain imaging protocols. Furthermore, spinal fluid testing should incorporate quantitative IgG index determinations in addition to qualitative oligoclonal band detection. Future investigations will likely integrate emerging blood biomarkers, such as serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP), to enhance prognostic precision. In addition, machine learning models may refine risk calculations by combining automated volumetric MRI measurements with longitudinal clinical metrics. Until these molecular assays achieve universal clinical availability, the validated combination of age, spinal lesion load, onset symptoms, and intrathecal IgG synthesis provides an immediate, accessible prognostic framework. Implementing these multimodal baseline markers allows neurology teams to deliver targeted therapeutic regimens and preserve long-term functional reserve.

What are the strongest baseline predictors of disability accumulation in relapsing MS?

The primary independent predictors identified at diagnosis include intrathecal immunoglobulin G (IgG) synthesis, a higher baseline number of spinal cord lesions, older age at symptom onset, and polysymptomatic clinical manifestation. Patients exceeding thresholds for these markers face a substantially higher five-year risk of confirmed disability progression.

How do spinal cord lesions specifically affect MS disease progression?

Spinal cord lesions independently differentiate progression independent of relapse activity (PIRA) from relapse-associated worsening. Because the spinal cord houses critical motor and sensory tracts in a compact area, focal demyelination and axonal transection cause direct functional deficits and accelerate silent, long-term disability accumulation.

How should clinicians utilize baseline prognostic models to guide MS treatment?

Clinicians can use baseline prognostic risk scores to personalize disease-modifying therapy selection. Patients demonstrating high-risk baseline profiles benefit from early initiation of high-efficacy DMTs to prevent permanent neurological injury. Meanwhile, patients with low-risk features can be monitored closely with tailored therapy choices and regular neuroimaging surveillance.

Disclaimer: This content is for informational and educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment. It does not replace professional clinical judgment. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Lauerer M et al. Predictors of early disability accumulation in newly diagnosed multiple sclerosis: clinical, imaging and cerebrospinal fluid measures. J Neurol Neurosurg Psychiatry. 2025 Aug 14. doi: 10.1136/jnnp-2024-335037. PMID: 39961655.


2. Sharmin S, Malpas CB, Roos I, et al. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry. J Neurol Neurosurg Psychiatry. 2022;93(12):1289-1296.


3. Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the 'real MS'. Ther Adv Neurol Disord. 2022;15:17562864211066751.